LivaNova PLC Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LivaNova PLC on October 6, 2023. The filing reports corporate governance changes regarding the Board of Directors effective as of the report date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and departures.
Material Changes
- Appointment of Director: J. Christopher Barry was appointed to the Board of Directors and the Audit and Compliance Committee on October 6, 2023. Mr. Barry brings over 20 years of medical technology experience, including former roles as CEO of NuVasive, Inc. and President of Surgical Innovations at Medtronic plc.
- Compensation for New Director: Mr. Barry will receive an annual board retainer of $110,000, an Audit and Compliance Committee fee of $15,000, and a restricted stock award with a fair market value of $130,000. These amounts are prorated for fiscal 2023.
- Departure of Director: Andrea Saia notified the Company of her decision to retire from the Board, effective December 31, 2023. The departure is not the result of any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It confirms no undisclosed arrangements or transactions involving the new director.
Investor Verification Checklist
- Verify the effective date of Andrea Saia's retirement (December 31, 2023) and its impact on Board quorum.
- Confirm the prorated compensation details for J. Christopher Barry for the remainder of fiscal 2023.
- Review the Company's Remuneration Policy to understand the standard compensation structure for non-employee directors.